Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C

Annals of Internal Medicine

Volumn 127, Issue 10, 1997, Pages 866-874

  Kim, W Ray ^a   Poterucha, John J ^a   Hermans, John E ^a   Therneau, Terry M ^a   Dickson, E Rolland ^a   Evans, Roger W ^a   Gross Jr , John B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; MATHEMATICAL MODEL; PRIORITY JOURNAL;

EID: 0030671562     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-10-199711150-00002     Document Type: Article

References (49)

1. Hepatitis Branch, Centers for Disease Control and Prevention. 1997 Hepatitis C Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; 1997.
2. Hoofnagle JH, Lau D. Chronic viral hepatitis-benefits of current therapies (Editorial]. N Engl J Med. 1996;334:1470-1.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrilo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-6.
4. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989; 321:1506-10.
5. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVento Viral Hepatitis Group. Hepatology. 1995;22:700-6.
6. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three Interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 1995;332:1457-62.
7. Koretz RL. Interferon and chronic non-A, non-B hepatitis: whom are we treating? Hepatology. 1990;12:613-5.
8. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology. 1995;22:1863-73.
9. Bennett WG, Inoue Y, Beck JR, Paulker SG, Davis GL. Justification of a single 6-month course of interferon for histologically mild chronic hepatitis C [Abstract]. Hepatology. 1995;22(S):290A.
10. Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol. 1992;27:812-6.
11. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. 1992;16:273-81.
12. Vaquer P, Canet R, Llompart A, Riera J, Ovrador A, Gaya J. Histological evolution of chronic hepatitis C: factors related to progression. Liver. 1994; 14:265-9.
13. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12.671-5.
14. Wejstal R, Hermodsson S, Norkrans G. Long-term follow-up of chronic hepatitis non-A, non-B - with special reference to hepatitis C. Liver. 1991;11: 143-8.
15. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut. 1993;(2 Suppl):S13-6.
16. Kiyosawa K, Tanaka E, Sodeyama T, Furuta S. Natural history of hepatitis C. Intervirology. 1994;37:101-7.
17. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991;14:969-74.
18. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88:240-3.
19. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122-8.
20. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-72.
21. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675-80.
22. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-801.
23. Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: recipient characteristics and outcome. In: Terasaki PI, Cecka JM, eds. Clinical Transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory; 1995:19-33.
24. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815-20.
25. National Center for Health Statistics. Vital Statistics of the United States, 1990. v II, Mortality, Part A. Washington. DC: Public Health Service; 1994.
26. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology. 1995;21:285-90.
27. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996;125:634-9.
28. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology. 1995;109:156-65.
29. Brown DM, Everhart JE. Cost of digestive diseases in the United States. In: Everhart JE, ed. Digestive Diseases in the United States: Epidemiology and Impact. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1994.
30. Evans RW. Liver transplantation in a managed care environment. Liver Transplantation and Surgery. 1995;1:61-75.
31. Kim WR, Therneau TM, Dickson ER, Evans RW. Preoperative predictors of resource utilization in liver transplantation. In: Terasaki PI, Cecka JM, eds. Clinical Transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory; 1995: 315-22.
32. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1995.
33. Petitti DB. Meta-Analysis, Decision-Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York: Oxford Univ Pr; 1994:119-24.
34. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications; 1987.
35. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study. N Engl J Med. 1992;327:1899-905.
36. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6.
37. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A non-B hepatitis. The National Heart, Lung, and Blood Institute Study. N Engl J Med. 1992;327: 1906-11.
38. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA. 1995;274:881-4.
39. Kinosian BP, Eisenberg JM. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;259:2249-54.
40. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393-7.
41. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology. 1991;13:327-31.
42. Friedlander L, van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T. New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease. Dig Dis Sci. 1996;41:1678-81.
43. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989;262:2879-86.
44. Avorn J. Benefit and cost analysis in geriatric care: turning age discrimination into health policy. N Engl J Med. 1984;310:1294-301.
45. Ampurdanes S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol. 1996;25:827-32.
46. Wong LL, McFall P, Wong LM. The cost of dying of end-stage liver disease. Arch Intern Med. 1997;157:1429-32.
47. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther. 1994;16:334-43.
48. La Puma J, Lawler EF. Quality-adjusted life-years. Ethical implications for physicians and policymakers. JAMA. 1990;263:2917-21.
49. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41